United Therapeutics (UTHR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

United Therapeutics (UTHR) reported $735.9 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 19.7%. EPS of $6.19 for the same period compares to $4.36 a year ago.The reported revenue represents a surprise of +1.46% over the Zacks Consensus Estimate of $725.32 million. With the consensus EPS estimate being $6.10, the EPS surprise was +1.48%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how United Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Other products- U.S. $4.20 million versus the two-analyst average estimate of $2.25 million. Revenues- United States: $705.70 million versus $681.36 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +20.5% change. Revenues- Rest-of-World: $30.20 million compared to the $30.17 million average estimate based on two analysts. The reported number represents a change of +4.9% year over year. Revenues- Unituxin- U.S. $61.80 million versus the two-analyst average estimate of $49.86 million. Revenues- Adcirca: $4.70 million compared to the $6.10 million average estimate based on seven analysts. The reported number represents a change of -30.9% year over year. Revenues- Orenitram: $107.80 million compared to the $109.01 million average estimate based on seven analysts. The reported number represents a change of +28.2% year over year. Revenues- Remodulin: $134.50 million versus $117.28 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +16.9% change. Revenues- Tyvaso: $415.90 million versus the six-analyst average estimate of $425.28 million. The reported number represents a year-over-year change of +94.6%. Revenues- Unituxin: $67.50 million versus $59.93 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +24.5% change. Revenue- Nebulized Tyvaso: $142.70 million versus $149.34 million estimated by five analysts on average. Revenue- Tyvaso DPI: $273.20 million versus $282.26 million estimated by five analysts on average. Revenues- Other products: $5.50 million versus $4.90 million estimated by four analysts on average. View all Key Company Metrics for United Therapeutics here>>>Shares of United Therapeutics have returned -3.6% over the past month versus the Zacks S&P 500 composite's -2.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report United Therapeutics Corporation (UTHR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks